Alloy Therapeutics raised $40 million in a late-stage Series E funding round to scale its tech-enabled biotech infrastructure. The company said it will use the capital across discovery engine expansion, additional preclinical and clinical development work, and a broader data and AI layer intended to connect projects across the platform. Alloy framed the financing as strategic capital aligned with its infrastructure-to-partnership model rather than a classic go-to-market bet tied to a single pipeline. The firm said it collaborates with more than 200 partners and has generated 100 licensed therapeutic programs, positioning the funding to extend that external development engine. Investors included 8VC, JIC Venture Growth Investments, and Echo Capital, with participation from returning backers such as Mubadala Capital and Thiel Capital.